Drugs such as Ozempic, Wegovy and Zepbound were expected to change how obesity is discussed in medicine and everyday life. By treating weight as a medical condition rather than a personal failure, GLP-1 medications seemed to offer a path away from older, judgmental views about body size.
But that shift has not fully happened. Patients using these medications say they still feel judged by people close to them, including friends and relatives, and in some cases by their own doctors. The reports suggest that even as treatment options evolve, social attitudes toward obesity remain deeply rooted.
The tension highlights a larger problem around obesity bias. If patients are still made to feel ashamed for seeking treatment, the broader promise of GLP-1 drugs goes beyond appetite or weight loss and runs into a cultural barrier that medicine alone cannot quickly remove.
In that sense, the issue is not only whether Ozempic or similar drugs work. It is also whether the growing use of GLP-1 medications can truly change the stigma attached to obesity, or whether patients will continue to face suspicion and blame despite a new era of treatment.
